Nasal T cell lymphoma: a rare entity

J Coll Physicians Surg Pak. 2014 Mar:24 Suppl 1:S50-1.

Abstract

Nasal type of Natural Killer (NK)/T cell lymphoma manifests in the nasal cavity. Approximately 95% of them are associated with EBV(Ebstein Barr Virus) with a strong predilection for the Asian population. It has certain systemic and localized symptoms which aid in diagnosis of the condition. However, the histological criteria is pivotal in confirming the diagnosis as well as aiding in confirming the association of EBV. Nasal type of NK/T cell lymphoma has a guarded prognosis. Treatment plan include radiotherapy with concurrent chemotherapy. Despite all this, the 5-year survival rate ranges from 15-75%. A 35 years old male presented with an ulcerative nasal lesion. Diagnosed as nasal type of NK/T cell lymphoma via a tissue biopsy, it was managed by chemo-radiotherapy leading to complete resolution of symptoms and disease free on his follow-up 6 months later.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antigens, Neoplasm / analysis*
  • Antineoplastic Combined Chemotherapy Protocols
  • Biopsy
  • CD56 Antigen / analysis*
  • Chemoradiotherapy
  • Cyclophosphamide
  • Doxorubicin
  • Humans
  • Killer Cells, Natural / pathology*
  • Lymphoma, T-Cell / immunology
  • Lymphoma, T-Cell / pathology*
  • Lymphoma, T-Cell / therapy
  • Male
  • Nasal Cavity / pathology
  • Nose Neoplasms / immunology
  • Nose Neoplasms / pathology*
  • Nose Neoplasms / therapy
  • Prednisone
  • Treatment Outcome
  • Vincristine

Substances

  • Antigens, Neoplasm
  • CD56 Antigen
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol